Dr. Mathai Mammen Joins General Atlantic as Senior Advisor Focused on Life Sciences

NEW YORK--(BUSINESS WIRE)--General Atlantic, a leading global growth equity firm, announced today that Mathai Mammen, M.D., Ph.D., has joined the firm as a Senior Advisor. In his role, Dr. Mammen will provide strategic counsel and advise the firm’s Life Sciences investment team and portfolio companies.

Dr. Mammen brings more than 25 years of leadership experience in the biopharmaceutical industry, focusing on drug discovery, development and scaling of small and large businesses. He is the incoming Chairman, President and Chief Executive Officer of FogPharma, a biopharmaceutical company committed to transforming the lives of patients through a new precision medicine approach widely applicable to important and challenging disease targets.

Before assuming his role at FogPharma in 2023, Dr. Mammen was Executive Vice President of Pharmaceuticals, R&D at Johnson & Johnson and served on the Executive Committee. Dr. Mammen is credited for spearheading initiatives and strategies at Janssen’s R&D and propelled the company to global recognition as one of the largest and most successful R&D organizations and one of the leading pharmaceutical companies in the world. He also played a critical role in leading Johnson & Johnson’s expansion in COVID vaccines. Prior to Johnson & Johnson, he held R&D roles at Merck, Inc. and Theravance, a company he co-founded in 1997 following his studies and research at Harvard University.

“Mathai is one our industry’s most respected R&D leaders,” said Brett Zbar, Managing Director and Global Head of Life Sciences at General Atlantic. “As anyone who knows Mathai is aware, he is an enlightened thinker, who deeply understands the next generation of advanced life science technologies. He is committed to advancing only high-impact therapeutics and has a global mindset. We’re thrilled he is sharing his expertise with our team.”

"We are at the brink of a revolution in precision medicine, and seeing this transformation through will require advances in science and data science, global collaboration and dedicated capital,” commented Dr. Mathai Mammen. “I am thrilled to advise the General Atlantic team as the firm leverages its powerful global platform to support entrepreneurs driving pivotal innovations in the Life Sciences.”

Dr. Mammen received his M.D. from the Harvard Medical School and Massachusetts Institute of Technology HST program, a Ph.D. in Chemistry from Harvard University and a BSc in Chemistry from Dalhousie University. Dr. Mammen currently serves on the board of directors of 10x Genomics, Inc. He is also a long-standing advisor to Foresite Capital, a leading multi-stage healthcare and life sciences investment firm.

About General Atlantic

General Atlantic is a leading global growth equity firm with more than four decades of experience providing capital and strategic support for over 495 growth companies throughout its history. Established in 1980 to partner with visionary entrepreneurs and deliver lasting impact, the firm combines a collaborative global approach, sector specific expertise, a long-term investment horizon and a deep understanding of growth drivers to partner with great entrepreneurs and management teams to scale innovative businesses around the world. General Atlantic has more than $72 billion in assets under management inclusive of all products as of December 31, 2022, and more than 220 investment professionals based in New York, Amsterdam, Beijing, Hong Kong, Jakarta, London, Mexico City, Miami, Mumbai, Munich, San Francisco, São Paulo, Shanghai, Singapore, Stamford and Tel Aviv. For more information on General Atlantic, please visit: www.generalatlantic.com.